Loading...

Primary Health Properties

DB:PP51
Snowflake Description

6 star dividend payer with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PP51
DB
£1B
Market Cap
  1. Home
  2. DE
  3. Real Estate
Company description

Primary Health Properties PLC (“PHP”) is a UK Real Estate Investment Trust (“REIT”) and the leading investor in modern primary healthcare premises. The last earnings update was 72 days ago. More info.


Add to Portfolio Compare Print
PP51 Share Price and Events
7 Day Returns
-1.3%
DB:PP51
-0.5%
Europe REITs
1.8%
DE Market
1 Year Returns
20.9%
DB:PP51
-2.4%
Europe REITs
-6%
DE Market
PP51 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Primary Health Properties (PP51) -1.3% 1.6% 15.5% 20.9% 13.2% 40.5%
Europe REITs -0.5% 0.7% 5.9% -2.4% 3.2% 14.8%
DE Market 1.8% 4.2% 7.4% -6% 10.1% 15.4%
1 Year Return vs Industry and Market
  • PP51 outperformed the REITs industry which returned -2.4% over the past year.
  • PP51 outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
PP51
Industry
5yr Volatility vs Market

PP51 Value

 Is Primary Health Properties undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Primary Health Properties to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Primary Health Properties.

DB:PP51 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity using Adjusted Funds From Operations
Levered Adjusted Funds From Operations Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.7%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:PP51
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6.7%
REITs Unlevered Beta Simply Wall St/ S&P Global 0.54
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.538 (1 + (1- 19%) (46.75%))
0.827
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.83
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (0.827 * 6.65%)
5.73%

Discounted Cash Flow Calculation for DB:PP51 using 2 Stage Free Cash Flow to Equity using Adjusted Funds From Operations Model

The calculations below outline how an intrinsic value for Primary Health Properties is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Primary Health Properties is a Real Estate Investment Trust (REIT), we use funds from operations (FFO) or adjusted funds from operations (AFFO) instead of levered free cash flow for REITs. This excludes depreciation and borrowing. Ideally analysts estimates of AFFO are used, where these aren't available we use FFO.

DB:PP51 DCF 1st Stage: Next 10 year cash flow forecast
Adjusted Funds From Operations (AFFO) (GBP, Millions) Source Present Value
Discounted (@ 5.73%)
2019 49.00 Analyst x1 46.35
2020 67.30 Analyst x1 60.20
2021 70.10 Analyst x1 59.31
2022 80.57 Est @ 14.94% 64.48
2023 89.05 Est @ 10.52% 67.40
2024 95.67 Est @ 7.43% 68.49
2025 100.71 Est @ 5.27% 68.19
2026 104.50 Est @ 3.76% 66.92
2027 107.32 Est @ 2.7% 65.01
2028 109.42 Est @ 1.96% 62.69
Present value of next 10 years cash flows £629.04
DB:PP51 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= £109.42 × (1 + 0.23%) ÷ (5.73% – 0.23%)
£1,993.90
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= £1,993.90 ÷ (1 + 5.73%)10
£1,142.32
DB:PP51 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= £629.04 + £1,142.32
£1,771.36
Equity Value per Share
(GBP)
= Total value / Shares Outstanding
= £1,771.36 / 1,134.67
£1.54
DB:PP51 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:PP51 represents 1.1422x of LSE:PHP
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
1.1422x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (GBP) x Listing Adjustment Factor
= £ 1.54 x 1.1422
€1.76
Value per share (EUR) From above. €1.76
Current discount Discount to share price of €1.49
= -1 x (€1.49 - €1.76) / €1.76
15.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Primary Health Properties is available for.
Intrinsic value
15%
Share price is €1.49 vs Future cash flow value of €1.76
Current Discount Checks
For Primary Health Properties to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Primary Health Properties's share price is below the future cash flow value, but not at a moderate discount (< 20%).
  • Primary Health Properties's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Primary Health Properties's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Primary Health Properties's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:PP51 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in GBP £0.10
LSE:PHP Share Price ** LSE (2019-04-18) in GBP £1.31
Europe REITs Industry PE Ratio Median Figure of 125 Publicly-Listed REITs Companies 12.27x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Primary Health Properties.

DB:PP51 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= LSE:PHP Share Price ÷ EPS (both in GBP)

= 1.31 ÷ 0.10

12.47x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Primary Health Properties is overvalued based on earnings compared to the Europe REITs industry average.
  • Primary Health Properties is good value based on earnings compared to the Germany market.
Price based on expected Growth
Does Primary Health Properties's expected growth come at a high price?
Raw Data
DB:PP51 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 12.47x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
22%per year
Europe REITs Industry PEG Ratio Median Figure of 61 Publicly-Listed REITs Companies 0.57x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

DB:PP51 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 12.47x ÷ 22%

0.57x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Primary Health Properties is good value based on expected growth next year.
Price based on value of assets
What value do investors place on Primary Health Properties's assets?
Raw Data
DB:PP51 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in GBP £1.02
LSE:PHP Share Price * LSE (2019-04-18) in GBP £1.31
Europe REITs Industry PB Ratio Median Figure of 149 Publicly-Listed REITs Companies 0.98x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.84x
DB:PP51 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= LSE:PHP Share Price ÷ Book Value per Share (both in GBP)

= 1.31 ÷ 1.02

1.28x

* Primary Listing of Primary Health Properties.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Primary Health Properties is overvalued based on assets compared to the Europe REITs industry average.
X
Value checks
We assess Primary Health Properties's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the REITs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the REITs industry average (and greater than 0)? (1 check)
  5. Primary Health Properties has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

PP51 Future Performance

 How is Primary Health Properties expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
22%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Primary Health Properties expected to grow at an attractive rate?
  • Primary Health Properties's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Primary Health Properties's earnings growth is expected to exceed the Germany market average.
  • Primary Health Properties's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:PP51 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:PP51 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 22%
DB:PP51 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 16.6%
Europe REITs Industry Earnings Growth Rate Market Cap Weighted Average 7.4%
Europe REITs Industry Revenue Growth Rate Market Cap Weighted Average 2.6%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:PP51 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in GBP Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:PP51 Future Estimates Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 140 124 123 5
2020-12-31 132 118 114 5
2019-12-31 115 92 59 5
DB:PP51 Past Financials Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income *
2018-12-31 80 69 74
2018-09-30 78 66 80
2018-06-30 76 64 86
2018-03-31 74 62 89
2017-12-31 73 60 92
2017-09-30 71 60 77
2017-06-30 70 60 63
2017-03-31 69 59 53
2016-12-31 67 57 44
2016-09-30 66 56 46
2016-06-30 65 55 49
2016-03-31 64 56 53

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Primary Health Properties's earnings are expected to grow significantly at over 20% yearly.
  • Primary Health Properties's revenue is expected to grow by 16.6% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:PP51 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Primary Health Properties Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:PP51 Future Estimates Data
Date (Data in GBP Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 0.11 0.12 0.11 2.00
2020-12-31 0.11 0.11 0.10 2.00
2019-12-31 0.03 0.03 0.03 1.00
DB:PP51 Past Financials Data
Date (Data in GBP Millions) EPS *
2018-12-31 0.10
2018-09-30 0.12
2018-06-30 0.13
2018-03-31 0.14
2017-12-31 0.15
2017-09-30 0.13
2017-06-30 0.10
2017-03-31 0.09
2016-12-31 0.08
2016-09-30 0.09
2016-06-30 0.10
2016-03-31 0.11

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Primary Health Properties will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Primary Health Properties's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Primary Health Properties has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

PP51 Past Performance

  How has Primary Health Properties performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Primary Health Properties's growth in the last year to its industry (REITs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Primary Health Properties has delivered over 20% year on year earnings growth in the past 5 years.
  • Primary Health Properties's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Primary Health Properties's 1-year earnings growth is negative, it can't be compared to the Europe REITs industry average.
Earnings and Revenue History
Primary Health Properties's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Primary Health Properties Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:PP51 Past Revenue, Cash Flow and Net Income Data
Date (Data in GBP Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 79.60 74.30 9.90
2018-09-30 77.85 80.30 9.75
2018-06-30 76.10 86.30 9.60
2018-03-31 74.30 89.10 9.15
2017-12-31 72.50 91.90 8.70
2017-09-30 71.30 77.20 8.20
2017-06-30 70.10 62.50 7.70
2017-03-31 68.75 53.10 7.50
2016-12-31 67.40 43.70 7.30
2016-09-30 66.07 46.41 7.11
2016-06-30 64.74 49.12 6.92
2016-03-31 63.93 52.57 6.86
2015-12-31 63.12 56.03 6.81
2015-09-30 62.30 51.64 6.65
2015-06-30 61.48 47.25 6.49
2015-03-31 60.73 42.07 6.64
2014-12-31 59.99 36.88 6.78
2014-09-30 55.88 32.78 6.83
2014-06-30 51.77 28.68 6.87
2014-03-31 46.87 24.45 6.48
2013-12-31 41.98 20.22 6.08
2013-09-30 39.31 15.39 5.75
2013-06-30 36.63 10.55 5.42
2013-03-31 34.89 5.84 5.27
2012-12-31 33.15 1.13 5.12
2012-09-30 32.39 2.99 5.19
2012-06-30 31.64 4.86 5.27

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Primary Health Properties has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Primary Health Properties used its assets more efficiently than the Europe REITs industry average last year based on Return on Assets.
  • Primary Health Properties's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Primary Health Properties's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the REITs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Primary Health Properties has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

PP51 Health

 How is Primary Health Properties's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Primary Health Properties's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Primary Health Properties's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Primary Health Properties's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Primary Health Properties's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Primary Health Properties Company Filings, last reported 3 months ago.

DB:PP51 Past Debt and Equity Data
Date (Data in GBP Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 788.00 693.90 5.90
2018-09-30 788.00 693.90 5.90
2018-06-30 730.60 670.60 12.10
2018-03-31 730.60 670.60 12.10
2017-12-31 586.80 755.20 4.10
2017-09-30 586.80 755.20 4.10
2017-06-30 530.60 718.50 8.10
2017-03-31 530.60 718.50 8.10
2016-12-31 499.20 701.70 5.10
2016-09-30 499.20 701.70 5.10
2016-06-30 492.42 676.62 6.06
2016-03-31 492.42 676.62 6.06
2015-12-31 345.36 733.03 2.88
2015-09-30 345.36 733.03 2.88
2015-06-30 334.28 717.80 1.52
2015-03-31 334.28 717.80 1.52
2014-12-31 309.13 708.29 12.07
2014-09-30 309.13 708.29 12.07
2014-06-30 312.98 654.29 6.28
2014-03-31 312.98 654.29 6.28
2013-12-31 302.39 625.46 9.29
2013-09-30 302.39 625.46 9.29
2013-06-30 260.18 385.97 14.62
2013-03-31 260.18 385.97 14.62
2012-12-31 179.09 454.43 25.10
2012-09-30 179.09 454.43 25.10
2012-06-30 185.69 346.84 0.96
  • Primary Health Properties's level of debt (88.1%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (206.9% vs 88.1% today).
  • Debt is not well covered by operating cash flow (9.9%, less than 20% of total debt).
  • Interest payments on debt are not well covered by earnings (EBIT is 2.4x annual interest expense, ideally 3x coverage).
X
Financial health checks
We assess Primary Health Properties's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Primary Health Properties has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

PP51 Dividends

 What is Primary Health Properties's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
4.28%
Current annual income from Primary Health Properties dividends. Estimated to be 4.38% next year.
If you bought €2,000 of Primary Health Properties shares you are expected to receive €86 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Primary Health Properties's pays a higher dividend yield than the bottom 25% of dividend payers in Germany (1.43%).
  • Primary Health Properties's dividend is above the markets top 25% of dividend payers in Germany (3.72%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:PP51 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe REITs Industry Average Dividend Yield Market Cap Weighted Average of 119 Stocks 4.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:PP51 Future Dividends Estimate Data
Date (Data in £) Dividend per Share (annual) Avg. No. Analysts
2021-12-31 0.06 5.00
2020-12-31 0.06 6.00
2019-12-31 0.06 6.00
DB:PP51 Past Annualized Dividends Data
Date (Data in £) Dividend per share (annual) Avg. Yield (%)
2019-03-28 0.056 4.287
2019-01-03 0.056 4.692
2018-10-03 0.054 4.911
2018-07-04 0.054 4.722
2018-03-27 0.054 4.791
2018-01-03 0.054 4.695
2017-10-05 0.053 4.551
2017-07-06 0.052 4.440
2017-03-30 0.052 4.633
2017-01-05 0.052 4.828
2016-10-06 0.051 4.627
2016-07-07 0.051 4.610
2016-01-04 0.051 4.861
2015-08-20 0.050 4.731
2015-02-19 0.050 5.048
2015-02-18 0.050 5.155
2014-08-21 0.049 5.496
2014-04-10 0.048 5.542
2014-02-27 0.049 5.632
2014-02-20 0.049 5.379
2013-08-22 0.048 5.612
2013-02-28 0.048 5.762
2012-08-22 0.046 5.357
2012-07-16 0.046 5.599
2012-02-21 0.046 5.753
2012-02-20 0.046 5.703
2011-08-18 0.045 5.724
2011-02-24 0.045 5.657
2011-02-23 0.045 5.467
2010-08-19 0.044 5.454
2010-02-25 0.044 6.008
2009-08-18 0.043 5.836
2009-04-21 0.043 6.724

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been stable in the past 10 years.
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of Primary Health Properties's earnings are paid to the shareholders as a dividend.
  • Dividends paid are covered by earnings (2x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be covered by earnings (1.1x coverage).
X
Income/ dividend checks
We assess Primary Health Properties's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Primary Health Properties afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Primary Health Properties has a total score of 6/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

PP51 Management

 What is the CEO of Primary Health Properties's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Harry Hyman
COMPENSATION £41,875
AGE 61
TENURE AS CEO 23.2 years
CEO Bio

Mr. Harry Abraham Hyman is the Founder of Primary Health Properties PLC and serves as its Managing Director since February 5, 1996. Mr. Hyman has been a Director at Primary Health Properties PLC since February 1996. He serves as the Managing Director of Nexus Tradeco Limited and is the Adviser at Nexus Management Services Limited. Mr. Hyman is the Company Secretary at Nexus Group. He is a Co-Founder of General Medical Clinics PLC. Mr. Hyman joined Baltic PLC in 1983 and served as its Deputy Managing Director, Finance Director and Company Secretary. He serves as the Non-Executive Chairman of General Medical Clinics PLC and has been its Director since 1998. He serves as the Non-Executive Chairman of Derriston Capital PLC. Mr. Hyman has been the Non-Executive Chairman at Summit Germany Limited since February 14, 2014. He serves as a Senior Independent Director at BioPharma Credit PLC. He serves as Director of JO Hambro Capital Management Limited, Dr Foster Limited and PHP Bond Finance PLC. Mr. Hyman also serves as Non-Executive Director of BFS Managed Properties Ltd., Intrinsic Value PLC and Pharmacy 2U Ltd. He serves as a Non-Executive Director of the QCA. Mr. Hyman served as a Non-Executive Director of Royal London UK Equity & Income Trust PLC since September 04, 2001, Royal London Asset Management Limited and Royal London UK Equity & Income Securities Plc since September 4, 2001. He served as Senior Independent Non-Executive Director of Groupe Chez Gerard PLC. Mr. Hyman served as a Director of Aberdeen High Income Trust PLC and Aberdeen Preferred Income Trust plc. He served as a Director of Greener House Investments PLC since June 22, 2007. He is the Founder of The International Opera Awards. He is a Fellow of the Institute of Chartered Accountants in England & Wales. Mr. Hyman is trained as Chartered Accountant and a Corporate Treasurer. He graduated from Cambridge University.

CEO Compensation
  • Harry's compensation has been consistent with company performance over the past year.
  • Harry's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the Primary Health Properties management team in years:

2.3
Average Tenure
  • The tenure for the Primary Health Properties management team is about average.
Management Team

Harry Hyman

TITLE
MD & Director
COMPENSATION
£42K
AGE
61
TENURE
23.2 yrs

Richard Howell

TITLE
Finance Director & Director
AGE
51
TENURE
2.1 yrs

Chris Santer

TITLE
Chief Investment Officer
TENURE
0.1 yrs

Paul Wright

TITLE
Company Secretary & Chief Legal Counsel
TENURE
2.6 yrs

Andrew Birch

TITLE
Head of Portfolio Management

Michelle Whitfield

TITLE
Head of Property Services

Dan Whitby

TITLE
Group Financial Controller
TENURE
1 yrs

Tim Walker-Arnott

TITLE
Advisory Director

David Austin

TITLE
Property Director

David Bateman

TITLE
Acquisitions Director
TENURE
4.6 yrs
Board of Directors Tenure

Average tenure and age of the Primary Health Properties board of directors in years:

1.1
Average Tenure
58
Average Age
  • The average tenure for the Primary Health Properties board of directors is less than 3 years, this suggests a new board.
Board of Directors

Steven Owen

TITLE
Independent Non-Executive Chairman
COMPENSATION
£44K
AGE
61
TENURE
1 yrs

Harry Hyman

TITLE
MD & Director
COMPENSATION
£42K
AGE
61
TENURE
23.2 yrs

Helen Mahy

TITLE
Non-Executive Deputy Chairman & Senior Independent Director
AGE
57
TENURE
0.1 yrs

Richard Howell

TITLE
Finance Director & Director
AGE
51
TENURE
2.1 yrs

Ian Krieger

TITLE
Independent Non-Executive Director
COMPENSATION
£43K
AGE
66
TENURE
1.2 yrs

Stephen Kell

TITLE
Independent Non-executive Director
COMPENSATION
£36K
AGE
45
TENURE
1.2 yrs

Peter William Cole

TITLE
Independent Non-Executive Director
COMPENSATION
£28K
AGE
59
TENURE
0.9 yrs

Laure, Briscoe Duhot

TITLE
Non-Executive Director
AGE
56
TENURE
0.1 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Primary Health Properties insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
14. Mar 19 Sell Smith & Williamson Investment Management LLP Company 13. Mar 19 13. Mar 19 -4,847 €1.47 €-7,121
14. Mar 19 Buy Smith & Williamson Investment Management LLP Company 13. Mar 19 13. Mar 19 4,847 €1.47 €7,137
13. Mar 19 Sell Smith & Williamson Investment Management LLP Company 12. Mar 19 12. Mar 19 -1,682 €1.44 €-2,415
13. Mar 19 Buy Smith & Williamson Investment Management LLP Company 12. Mar 19 12. Mar 19 1,530 €1.43 €2,194
08. Mar 19 Sell Smith & Williamson Investment Management LLP Company 07. Mar 19 07. Mar 19 -2,500 €1.42 €-3,541
08. Mar 19 Buy Smith & Williamson Investment Management LLP Company 07. Mar 19 07. Mar 19 19,800 €1.44 €28,559
07. Mar 19 Buy Smith & Williamson Investment Management LLP Company 06. Mar 19 06. Mar 19 1,240 €1.45 €1,797
06. Mar 19 Buy Smith & Williamson Investment Management LLP Company 05. Mar 19 05. Mar 19 12,000 €1.45 €17,406
05. Mar 19 Sell Smith & Williamson Investment Management LLP Company 04. Mar 19 04. Mar 19 -1,740 €1.44 €-2,508
05. Mar 19 Buy Smith & Williamson Investment Management LLP Company 04. Mar 19 04. Mar 19 17,374 €1.44 €25,066
01. Mar 19 Buy Smith & Williamson Investment Management LLP Company 28. Feb 19 28. Feb 19 2,052 €1.43 €2,926
28. Feb 19 Buy Smith & Williamson Investment Management LLP Company 27. Feb 19 27. Feb 19 5,500 €1.41 €7,770
26. Feb 19 Sell Smith & Williamson Investment Management LLP Company 25. Feb 19 25. Feb 19 -2,000 €1.39 €-2,773
26. Feb 19 Buy Smith & Williamson Investment Management LLP Company 25. Feb 19 25. Feb 19 94,505 €1.39 €130,963
25. Feb 19 Buy Smith & Williamson Investment Management LLP Company 22. Feb 19 22. Feb 19 26,000 €1.38 €35,977
22. Feb 19 Buy Smith & Williamson Investment Management LLP Company 21. Feb 19 21. Feb 19 29,757 €1.38 €40,996
21. Feb 19 Buy Smith & Williamson Investment Management LLP Company 20. Feb 19 20. Feb 19 18,380 €1.36 €25,076
20. Feb 19 Sell Smith & Williamson Investment Management LLP Company 19. Feb 19 19. Feb 19 -3,250 €1.36 €-4,418
20. Feb 19 Buy Smith & Williamson Investment Management LLP Company 19. Feb 19 19. Feb 19 5,600 €1.36 €7,627
18. Feb 19 Buy Smith & Williamson Investment Management LLP Company 15. Feb 19 15. Feb 19 10,000 €1.33 €13,304
14. Feb 19 Buy Smith & Williamson Investment Management LLP Company 13. Feb 19 13. Feb 19 3,350 €1.32 €4,437
13. Feb 19 Buy Smith & Williamson Investment Management LLP Company 12. Feb 19 12. Feb 19 22,961 €1.32 €30,380
12. Feb 19 Sell Smith & Williamson Investment Management LLP Company 11. Feb 19 11. Feb 19 -4,500 €1.33 €-6,007
12. Feb 19 Buy Smith & Williamson Investment Management LLP Company 11. Feb 19 11. Feb 19 67,800 €1.34 €90,448
11. Feb 19 Sell Smith & Williamson Investment Management LLP Company 08. Feb 19 08. Feb 19 -4,000 €1.34 €-5,348
11. Feb 19 Buy Smith & Williamson Investment Management LLP Company 08. Feb 19 08. Feb 19 6,500 €1.33 €8,670
08. Feb 19 Sell Smith & Williamson Investment Management LLP Company 07. Feb 19 07. Feb 19 -11,580 €1.33 €-15,378
08. Feb 19 Buy Smith & Williamson Investment Management LLP Company 07. Feb 19 07. Feb 19 30,851 €1.33 €41,005
07. Feb 19 Buy Smith & Williamson Investment Management LLP Company 06. Feb 19 06. Feb 19 27,500 €1.32 €36,415
06. Feb 19 Buy Smith & Williamson Investment Management LLP Company 05. Feb 19 05. Feb 19 41,041 €1.32 €54,165
05. Feb 19 Sell Smith & Williamson Investment Management LLP Company 04. Feb 19 04. Feb 19 -2,640 €1.33 €-3,506
04. Feb 19 Buy Smith & Williamson Investment Management LLP Company 01. Feb 19 01. Feb 19 21,850 €1.32 €28,798
01. Feb 19 Sell Smith & Williamson Investment Management LLP Company 31. Jan 19 31. Jan 19 -7,000 €1.33 €-9,321
01. Feb 19 Buy Smith & Williamson Investment Management LLP Company 31. Jan 19 31. Jan 19 8,331 €1.34 €11,179
31. Jan 19 Buy Smith & Williamson Investment Management LLP Company 30. Jan 19 30. Jan 19 2,454 €1.33 €3,266
31. Jan 19 Sell Smith & Williamson Investment Management LLP Company 29. Jan 19 29. Jan 19 -5,000 €1.32 €-6,610
31. Jan 19 Buy Smith & Williamson Investment Management LLP Company 29. Jan 19 29. Jan 19 2,000 €1.34 €2,673
29. Jan 19 Sell Smith & Williamson Investment Management LLP Company 28. Jan 19 28. Jan 19 -22,000 €1.32 €-28,977
28. Jan 19 Buy Smith & Williamson Investment Management LLP Company 25. Jan 19 25. Jan 19 60,960 €1.30 €79,028
14. Mar 19 Sell BlackRock, Inc. Company 13. Mar 19 13. Mar 19 -2,738 €1.48 €-4,065
14. Mar 19 Buy BlackRock, Inc. Company 13. Mar 19 13. Mar 19 1,658,545 €1.48 €2,462,538
14. Mar 19 Buy State Street Global Advisors, Inc. Company 13. Mar 19 13. Mar 19 191,948 €1.47 €282,909
14. Mar 19 Buy Searchlight Capital Partners Company 13. Mar 19 13. Mar 19 1,356,602 €1.48 €2,014,225
14. Mar 19 Sell Brewin Dolphin Limited Company 13. Mar 19 13. Mar 19 -7,500 €1.47 €-11,016
14. Mar 19 Buy Brewin Dolphin Limited Company 13. Mar 19 13. Mar 19 7,500 €1.47 €11,028
14. Mar 19 Buy Charles Stanley & Co. Ltd, Asset Management Arm Company 13. Mar 19 13. Mar 19 22,780 €1.47 €33,517
13. Mar 19 Buy Legal & General Investment Management Limited Company 12. Mar 19 12. Mar 19 162,602 €1.43 €233,100
13. Mar 19 Sell Brewin Dolphin Limited Company 12. Mar 19 12. Mar 19 -6,000 €1.44 €-8,613
13. Mar 19 Sell Charles Stanley & Co. Ltd, Asset Management Arm Company 12. Mar 19 12. Mar 19 -18,864 €1.45 €-27,128
13. Mar 19 Buy Charles Stanley & Co. Ltd, Asset Management Arm Company 12. Mar 19 12. Mar 19 31,264 €1.43 €44,819
12. Mar 19 Sell Brewin Dolphin Limited Company 11. Mar 19 11. Mar 19 -5,000 €1.44 €-7,213
12. Mar 19 Buy Brewin Dolphin Limited Company 11. Mar 19 11. Mar 19 16,000 €1.44 €23,057
12. Mar 19 Sell Searchlight Capital Partners Company 11. Mar 19 11. Mar 19 -25,058 €1.44 €-35,963
12. Mar 19 Sell Valu-Trac Investment Management Limited Company 11. Mar 19 11. Mar 19 -6,026,618 €1.44 €-8,686,011
11. Mar 19 Buy BlackRock, Inc. Company 08. Mar 19 08. Mar 19 22,732 €1.43 €32,524
11. Mar 19 Sell Brewin Dolphin Limited Company 08. Mar 19 08. Mar 19 -4,400 €1.44 €-6,328
11. Mar 19 Buy Brewin Dolphin Limited Company 08. Mar 19 08. Mar 19 4,400 €1.44 €6,342
11. Mar 19 Sell Brooks MacDonald Asset Management Limited Company 08. Mar 19 08. Mar 19 -16,000 €1.44 €-23,003
11. Mar 19 Sell Charles Stanley & Co. Ltd, Asset Management Arm Company 08. Mar 19 08. Mar 19 -1,250 €1.44 €-1,797
11. Mar 19 Buy Charles Stanley & Co. Ltd, Asset Management Arm Company 08. Mar 19 08. Mar 19 3,993 €1.44 €5,745
08. Mar 19 Sell Amundi Asset Management Company 07. Mar 19 07. Mar 19 -820,334 €1.43 €-1,164,917
08. Mar 19 Sell Brooks MacDonald Asset Management Limited Company 06. Mar 19 06. Mar 19 -13,096 €1.44 €-18,853
05. Mar 19 Sell Brooks MacDonald Asset Management Limited Company 04. Mar 19 04. Mar 19 -8,480 €1.43 €-12,140
08. Mar 19 Buy BlackRock, Inc. Company 07. Mar 19 07. Mar 19 20,710 €1.45 €29,732
08. Mar 19 Buy State Street Global Advisors, Inc. Company 07. Mar 19 07. Mar 19 200,501 €1.43 €287,254
08. Mar 19 Sell Brooks MacDonald Asset Management Limited Company 07. Mar 19 07. Mar 19 -23,100 €1.41 €-32,605
08. Mar 19 Sell Charles Stanley & Co. Ltd, Asset Management Arm Company 07. Mar 19 07. Mar 19 -92,411 €1.43 €-130,949
08. Mar 19 Buy Charles Stanley & Co. Ltd, Asset Management Arm Company 07. Mar 19 07. Mar 19 3,100 €1.42 €4,394
08. Mar 19 Sell LGT Vestra LLP Company 07. Mar 19 07. Mar 19 -4,713 €1.41 €-6,666
08. Mar 19 Buy LGT Vestra LLP Company 07. Mar 19 07. Mar 19 8,500 €1.45 €12,305
07. Mar 19 Sell LGT Vestra LLP Company 25. Jan 19 05. Mar 19 -114,830 €1.45 €-155,259
07. Mar 19 Buy BlackRock, Inc. Company 06. Mar 19 06. Mar 19 4,277 €1.45 €6,198
07. Mar 19 Sell Brewin Dolphin Limited Company 06. Mar 19 06. Mar 19 -10,842 €1.45 €-15,690
07. Mar 19 Sell Charles Stanley & Co. Ltd, Asset Management Arm Company 06. Mar 19 06. Mar 19 -3,370 €1.45 €-4,888
06. Mar 19 Buy BlackRock, Inc. Company 05. Mar 19 05. Mar 19 11,411 €1.45 €16,531
06. Mar 19 Sell Brooks MacDonald Asset Management Limited Company 05. Mar 19 05. Mar 19 -13,529 €1.44 €-19,507
06. Mar 19 Sell Charles Stanley & Co. Ltd, Asset Management Arm Company 05. Mar 19 05. Mar 19 -9,450 €1.45 €-13,675
05. Mar 19 Sell Legal & General Investment Management Limited Company 04. Mar 19 04. Mar 19 -2,026 €1.44 €-2,924
05. Mar 19 Buy Legal & General Investment Management Limited Company 04. Mar 19 04. Mar 19 15,952 €1.44 €22,977
05. Mar 19 Buy BlackRock, Inc. Company 04. Mar 19 04. Mar 19 80,130 €1.44 €115,633
05. Mar 19 Sell Brewin Dolphin Limited Company 04. Mar 19 04. Mar 19 -3,272 €1.44 €-4,702
05. Mar 19 Buy Brewin Dolphin Limited Company 04. Mar 19 04. Mar 19 4,840 €1.44 €6,983
04. Mar 19 Sell Brooks MacDonald Asset Management Limited Company 01. Mar 19 01. Mar 19 -61,976 €1.43 €-88,608
04. Mar 19 Buy BlackRock, Inc. Company 01. Mar 19 01. Mar 19 20,609 €1.43 €29,529
04. Mar 19 Sell Brewin Dolphin Limited Company 01. Mar 19 01. Mar 19 -1,472 €1.43 €-2,109
04. Mar 19 Sell Charles Stanley & Co. Ltd, Asset Management Arm Company 01. Mar 19 01. Mar 19 -1,257 €1.43 €-1,801
04. Mar 19 Buy Charles Stanley & Co. Ltd, Asset Management Arm Company 01. Mar 19 01. Mar 19 24,842 €1.43 €35,622
01. Mar 19 Buy State Street Global Advisors, Inc. Company 28. Feb 19 28. Feb 19 271,779 €1.44 €390,136
01. Mar 19 Sell BlackRock, Inc. Company 28. Feb 19 28. Feb 19 -299,556 €1.43 €-429,635
01. Mar 19 Buy BlackRock, Inc. Company 28. Feb 19 28. Feb 19 42,784 €1.44 €61,427
01. Mar 19 Buy Brooks MacDonald Asset Management Limited Company 28. Feb 19 28. Feb 19 16,000 €1.42 €22,785
01. Mar 19 Sell Brewin Dolphin Limited Company 28. Feb 19 28. Feb 19 -18,529 €1.43 €-26,404
01. Mar 19 Buy Brewin Dolphin Limited Company 28. Feb 19 28. Feb 19 2,000 €1.44 €2,871
01. Mar 19 Sell Searchlight Capital Partners Company 28. Feb 19 28. Feb 19 -184 €1.44 €-264
28. Feb 19 Buy BlackRock, Inc. Company 27. Feb 19 27. Feb 19 3,530 €1.43 €5,031
28. Feb 19 Sell Legal & General Investment Management Limited Company 27. Feb 19 27. Feb 19 -62,911 €1.42 €-89,242
28. Feb 19 Sell Brewin Dolphin Limited Company 27. Feb 19 27. Feb 19 -8,434 €1.41 €-11,871
28. Feb 19 Sell Charles Stanley & Co. Ltd, Asset Management Arm Company 27. Feb 19 27. Feb 19 -35,000 €1.41 €-49,264
28. Feb 19 Buy Charles Stanley & Co. Ltd, Asset Management Arm Company 27. Feb 19 27. Feb 19 8,000 €1.42 €11,340
27. Feb 19 Buy BlackRock, Inc. Company 26. Feb 19 26. Feb 19 9,601 €1.40 €13,458
27. Feb 19 Sell Searchlight Capital Partners Company 26. Feb 19 26. Feb 19 -2,138 €1.40 €-2,997
27. Feb 19 Sell Charles Stanley & Co. Ltd, Asset Management Arm Company 26. Feb 19 26. Feb 19 -6,468 €1.40 €-9,087
27. Feb 19 Buy Charles Stanley & Co. Ltd, Asset Management Arm Company 26. Feb 19 26. Feb 19 2,763 €1.41 €3,884
26. Feb 19 Sell BlackRock, Inc. Company 25. Feb 19 25. Feb 19 -122,219 €1.38 €-168,962
26. Feb 19 Sell Brooks MacDonald Asset Management Limited Company 25. Feb 19 25. Feb 19 -24,500 €1.38 €-33,853
26. Feb 19 Sell Brewin Dolphin Limited Company 25. Feb 19 25. Feb 19 -10,800 €1.39 €-14,960
26. Feb 19 Buy Charles Stanley & Co. Ltd, Asset Management Arm Company 25. Feb 19 25. Feb 19 29,390 €1.39 €40,735
25. Feb 19 Sell State Street Global Advisors, Inc. Company 22. Feb 19 22. Feb 19 -62,869 €1.38 €-86,835
25. Feb 19 Buy Nexus Central Management Services Limited Company 25. Feb 19 25. Feb 19 77,100 €1.39 €106,799
25. Feb 19 Buy BlackRock, Inc. Company 22. Feb 19 22. Feb 19 1,412 €1.39 €1,961
25. Feb 19 Sell Charles Stanley & Co. Ltd, Asset Management Arm Company 22. Feb 19 22. Feb 19 -18,650 €1.38 €-25,719
22. Feb 19 Sell Legal & General Investment Management Limited Company 21. Feb 19 21. Feb 19 -16,094 €1.38 €-22,199
22. Feb 19 Sell State Street Global Advisors, Inc. Company 21. Feb 19 21. Feb 19 -10,640 €1.37 €-14,611
22. Feb 19 Buy Brewin Dolphin Limited Company 21. Feb 19 21. Feb 19 30,132 €1.37 €41,337
22. Feb 19 Buy Charles Stanley & Co. Ltd, Asset Management Arm Company 21. Feb 19 21. Feb 19 4,500 €1.38 €6,205
21. Feb 19 Buy Legal & General Investment Management Limited Company 20. Feb 19 20. Feb 19 25,512 €1.37 €34,830
21. Feb 19 Sell Citadel Group Limited Company 20. Feb 19 20. Feb 19 -8,900 €1.37 €-12,156
21. Feb 19 Buy Citadel Group Limited Company 20. Feb 19 20. Feb 19 5,347 €1.36 €7,288
21. Feb 19 Sell BlackRock, Inc. Company 20. Feb 19 20. Feb 19 -147,033 €1.37 €-200,826
21. Feb 19 Buy BlackRock, Inc. Company 20. Feb 19 20. Feb 19 66,372 €1.36 €90,280
21. Feb 19 Sell Brooks MacDonald Asset Management Limited Company 20. Feb 19 20. Feb 19 -14,740 €1.36 €-20,016
21. Feb 19 Sell State Street Global Advisors, Inc. Company 20. Feb 19 20. Feb 19 -8,489 €1.36 €-11,547
20. Feb 19 Buy Peter William Cole Individual 20. Feb 19 20. Feb 19 50,000 €1.36 €68,097
20. Feb 19 Sell State Street Global Advisors, Inc. Company 19. Feb 19 19. Feb 19 -15,366 €1.36 €-20,842
20. Feb 19 Sell BlackRock, Inc. Company 19. Feb 19 19. Feb 19 -77,346 €1.36 €-105,473
20. Feb 19 Buy BlackRock, Inc. Company 19. Feb 19 19. Feb 19 517,155 €1.36 €705,283
20. Feb 19 Sell Citadel Group Limited Company 19. Feb 19 19. Feb 19 -26,153 €1.36 €-35,632
20. Feb 19 Buy Citadel Group Limited Company 19. Feb 19 19. Feb 19 27,430 €1.36 €37,356
20. Feb 19 Buy Amundi Asset Management Company 19. Feb 19 19. Feb 19 260,000 €1.36 €354,837
20. Feb 19 Sell Brooks MacDonald Asset Management Limited Company 19. Feb 19 19. Feb 19 -12,733 €1.36 €-17,290
20. Feb 19 Buy Brewin Dolphin Limited Company 19. Feb 19 19. Feb 19 15,000 €1.36 €20,394
19. Feb 19 Sell Citadel Group Limited Company 18. Feb 19 18. Feb 19 -46,835 €1.34 €-62,898
19. Feb 19 Buy Citadel Group Limited Company 18. Feb 19 18. Feb 19 102,771 €1.34 €137,518
19. Feb 19 Sell BlackRock, Inc. Company 18. Feb 19 18. Feb 19 -51,726 €1.35 €-69,658
19. Feb 19 Buy Searchlight Capital Partners Company 18. Feb 19 18. Feb 19 14,527 €1.35 €19,563
19. Feb 19 Sell Brooks MacDonald Asset Management Limited Company 18. Feb 19 18. Feb 19 -1,000 €1.34 €-1,338
19. Feb 19 Sell Charles Stanley & Co. Ltd, Asset Management Arm Company 18. Feb 19 18. Feb 19 -13,538 €1.34 €-18,117
19. Feb 19 Buy Charles Stanley & Co. Ltd, Asset Management Arm Company 18. Feb 19 18. Feb 19 19,488 €1.34 €26,133
18. Feb 19 Sell Citadel Group Limited Company 15. Feb 19 15. Feb 19 -18,542 €1.33 €-24,686
18. Feb 19 Buy Citadel Group Limited Company 15. Feb 19 15. Feb 19 43,416 €1.33 €57,772
18. Feb 19 Sell Brooks MacDonald Asset Management Limited Company 15. Feb 19 15. Feb 19 -14,016 €1.32 €-18,535
18. Feb 19 Buy Brooks MacDonald Asset Management Limited Company 15. Feb 19 15. Feb 19 6,500 €1.32 €8,595
18. Feb 19 Buy Brewin Dolphin Limited Company 15. Feb 19 15. Feb 19 15,400 €1.33 €20,496
18. Feb 19 Sell Charles Stanley & Co. Ltd, Asset Management Arm Company 15. Feb 19 15. Feb 19 -213 €1.33 €-283
18. Feb 19 Buy Charles Stanley & Co. Ltd, Asset Management Arm Company 15. Feb 19 15. Feb 19 23,175 €1.33 €30,818
15. Feb 19 Sell Citadel Group Limited Company 14. Feb 19 14. Feb 19 -9,468 €1.32 €-12,482
15. Feb 19 Buy Citadel Group Limited Company 14. Feb 19 14. Feb 19 66,187 €1.32 €87,283
15. Feb 19 Sell Legal & General Investment Management Limited Company 14. Feb 19 14. Feb 19 -19,419 €1.32 €-25,663
15. Feb 19 Sell BlackRock, Inc. Company 14. Feb 19 14. Feb 19 -115,277 €1.31 €-151,562
15. Feb 19 Buy CCLA Investment Management Limited Company 14. Feb 19 14. Feb 19 18,635 €1.32 €24,543
15. Feb 19 Buy Brooks MacDonald Asset Management Limited Company 14. Feb 19 14. Feb 19 15,000 €1.31 €19,721
14. Feb 19 Sell BlackRock, Inc. Company 13. Feb 19 13. Feb 19 -10,952 €1.33 €-14,536
14. Feb 19 Buy State Street Global Advisors, Inc. Company 13. Feb 19 13. Feb 19 933 €1.33 €1,238
14. Feb 19 Buy Charles Stanley & Co. Ltd, Asset Management Arm Company 13. Feb 19 13. Feb 19 25,902 €1.32 €34,136
13. Feb 19 Buy BlackRock, Inc. Company 12. Feb 19 12. Feb 19 121,220 €1.32 €160,207
13. Feb 19 Buy State Street Global Advisors, Inc. Company 12. Feb 19 12. Feb 19 27,145 €1.32 €35,872
13. Feb 19 Sell Citadel Group Limited Company 11. Feb 19 11. Feb 19 -102,213 €1.34 €-135,920
13. Feb 19 Buy Citadel Group Limited Company 11. Feb 19 11. Feb 19 66,584 €1.34 €88,422
12. Feb 19 Buy BlackRock, Inc. Company 11. Feb 19 11. Feb 19 706 €1.33 €937
12. Feb 19 Buy State Street Global Advisors, Inc. Company 11. Feb 19 11. Feb 19 229,254 €1.34 €304,981
12. Feb 19 Sell UBS Asset Management Company 11. Feb 19 11. Feb 19 -105,747 €1.33 €-140,353
12. Feb 19 Sell Charles Stanley & Co. Ltd, Asset Management Arm Company 11. Feb 19 11. Feb 19 -7,940 €1.34 €-10,591
12. Feb 19 Buy Charles Stanley & Co. Ltd, Asset Management Arm Company 11. Feb 19 11. Feb 19 945 €1.34 €1,267
11. Feb 19 Buy Amundi Asset Management Company 08. Feb 19 08. Feb 19 70,680 €1.34 €94,478
11. Feb 19 Sell Citadel Group Limited Company 08. Feb 19 08. Feb 19 -9,849 €1.34 €-13,148
11. Feb 19 Buy Citadel Group Limited Company 08. Feb 19 08. Feb 19 18,819 €1.34 €25,053
11. Feb 19 Buy State Street Global Advisors, Inc. Company 08. Feb 19 08. Feb 19 224,568 €1.33 €299,744
11. Feb 19 Buy Brewin Dolphin Limited Company 08. Feb 19 08. Feb 19 42,695 €1.33 €56,949
11. Feb 19 Sell Brooks MacDonald Asset Management Limited Company 08. Feb 19 08. Feb 19 -4,600 €1.33 €-6,096
11. Feb 19 Sell Charles Stanley & Co. Ltd, Asset Management Arm Company 08. Feb 19 08. Feb 19 -6,800 €1.33 €-9,061
08. Feb 19 Sell Legal & General Investment Management Limited Company 07. Feb 19 07. Feb 19 -115,809 €1.33 €-153,864
08. Feb 19 Buy Legal & General Investment Management Limited Company 07. Feb 19 07. Feb 19 12,365 €1.33 €16,441
08. Feb 19 Sell Brooks MacDonald Asset Management Limited Company 07. Feb 19 07. Feb 19 -4,000 €1.33 €-5,300
08. Feb 19 Buy Brooks MacDonald Asset Management Limited Company 07. Feb 19 07. Feb 19 15,000 €1.33 €19,876
08. Feb 19 Buy State Street Global Advisors, Inc. Company 07. Feb 19 07. Feb 19 132,074 €1.33 €175,366
07. Feb 19 Buy Harry Hyman Individual 04. Feb 19 04. Feb 19 84 €1.33 €112
07. Feb 19 Buy Harry Hyman Individual 04. Feb 19 04. Feb 19 84 €1.33 €112
08. Feb 19 Sell Brewin Dolphin Limited Company 07. Feb 19 07. Feb 19 -13,200 €1.33 €-17,530
08. Feb 19 Buy Charles Stanley & Co. Ltd, Asset Management Arm Company 07. Feb 19 07. Feb 19 6,400 €1.33 €8,493
08. Feb 19 Buy Amundi Asset Management Company 07. Feb 19 07. Feb 19 2,109 €1.33 €2,795
07. Feb 19 Sell Brewin Dolphin Limited Company 06. Feb 19 06. Feb 19 -13,700 €1.32 €-18,120
07. Feb 19 Buy BlackRock, Inc. Company 06. Feb 19 06. Feb 19 26,610 €1.32 €35,191
07. Feb 19 Sell Charles Stanley & Co. Ltd, Asset Management Arm Company 06. Feb 19 06. Feb 19 -8,209 €1.33 €-10,888
07. Feb 19 Buy Charles Stanley & Co. Ltd, Asset Management Arm Company 06. Feb 19 06. Feb 19 8,010 €1.33 €10,593
06. Feb 19 Sell Amundi Asset Management Company 05. Feb 19 05. Feb 19 -230,925 €1.32 €-303,852
06. Feb 19 Buy Amundi Asset Management Company 05. Feb 19 05. Feb 19 25,000 €1.32 €32,895
06. Feb 19 Buy BlackRock, Inc. Company 05. Feb 19 05. Feb 19 75,059 €1.32 €99,104
06. Feb 19 Sell Brewin Dolphin Limited Company 05. Feb 19 05. Feb 19 -13,831 €1.32 €-18,234
06. Feb 19 Buy Brewin Dolphin Limited Company 05. Feb 19 05. Feb 19 4,200 €1.32 €5,543
05. Feb 19 Buy Amundi Asset Management Company 04. Feb 19 04. Feb 19 158,419 €1.33 €209,982
05. Feb 19 Buy BlackRock, Inc. Company 04. Feb 19 04. Feb 19 21,065 €1.33 €28,018
05. Feb 19 Buy UBS Asset Management Company 04. Feb 19 04. Feb 19 41,916 €1.33 €55,751
05. Feb 19 Sell Brooks MacDonald Asset Management Limited Company 04. Feb 19 04. Feb 19 -1,000 €1.33 €-1,325
05. Feb 19 Buy Brewin Dolphin Limited Company 04. Feb 19 04. Feb 19 7,600 €1.33 €10,104
01. Feb 19 Sell Amundi Asset Management Company 25. Jan 19 25. Jan 19 -65,850 €1.29 €-85,165
04. Feb 19 Sell Citadel Group Limited Company 01. Feb 19 01. Feb 19 -151,435 €1.33 €-199,800
04. Feb 19 Buy Citadel Group Limited Company 01. Feb 19 01. Feb 19 82,741 €1.32 €109,150
04. Feb 19 Buy BlackRock, Inc. Company 01. Feb 19 01. Feb 19 6,182 €1.32 €8,180
04. Feb 19 Buy Brooks MacDonald Asset Management Limited Company 01. Feb 19 01. Feb 19 13,330 €1.31 €17,486
01. Feb 19 Buy BlackRock, Inc. Company 31. Jan 19 31. Jan 19 2,758 €1.32 €3,644
01. Feb 19 Sell Citadel Group Limited Company 31. Jan 19 31. Jan 19 -127,654 €1.34 €-169,636
01. Feb 19 Buy Citadel Group Limited Company 31. Jan 19 31. Jan 19 68,041 €1.34 €90,416
01. Feb 19 Sell Brewin Dolphin Limited Company 31. Jan 19 31. Jan 19 -16,760 €1.33 €-22,300
01. Feb 19 Buy Brewin Dolphin Limited Company 31. Jan 19 31. Jan 19 6,000 €1.32 €7,937
01. Feb 19 Sell State Street Global Advisors, Inc. Company 31. Jan 19 31. Jan 19 -5,238 €1.32 €-6,921
01. Feb 19 Buy State Street Global Advisors, Inc. Company 31. Jan 19 31. Jan 19 407,757 €1.34 €544,228
01. Feb 19 Sell Charles Stanley & Co. Ltd, Asset Management Arm Company 31. Jan 19 31. Jan 19 -13,791 €1.34 €-18,416
01. Feb 19 Buy Charles Stanley & Co. Ltd, Asset Management Arm Company 31. Jan 19 31. Jan 19 33,345 €1.34 €44,616
31. Jan 19 Sell Citadel Group Limited Company 30. Jan 19 30. Jan 19 -113,692 €1.34 €-151,361
31. Jan 19 Buy Citadel Group Limited Company 30. Jan 19 30. Jan 19 92,765 €1.34 €123,587
31. Jan 19 Buy BlackRock, Inc. Company 30. Jan 19 30. Jan 19 19,150 €1.34 €25,679
31. Jan 19 Buy State Street Global Advisors, Inc. Company 30. Jan 19 30. Jan 19 725,618 €1.33 €968,203
31. Jan 19 Sell Brooks MacDonald Asset Management Limited Company 30. Jan 19 30. Jan 19 -20,494 €1.33 €-27,200
31. Jan 19 Buy Brooks MacDonald Asset Management Limited Company 30. Jan 19 30. Jan 19 16,270 €1.33 €21,594
31. Jan 19 Sell Charles Stanley & Co. Ltd, Asset Management Arm Company 30. Jan 19 30. Jan 19 -2,610 €1.32 €-3,455
31. Jan 19 Buy Charles Stanley & Co. Ltd, Asset Management Arm Company 30. Jan 19 30. Jan 19 4,260 €1.34 €5,692
30. Jan 19 Buy Searchlight Capital Partners Company 29. Jan 19 29. Jan 19 26,046 €1.33 €34,710
28. Jan 19 Buy Searchlight Capital Partners Company 25. Jan 19 25. Jan 19 506,772 €1.30 €656,588
25. Jan 19 Buy Searchlight Capital Partners Company 24. Jan 19 24. Jan 19 855,625 €1.29 €1,101,190
30. Jan 19 Sell Citadel Group Limited Company 29. Jan 19 29. Jan 19 -34,248 €1.34 €-45,792
30. Jan 19 Buy Citadel Group Limited Company 29. Jan 19 29. Jan 19 127,994 €1.34 €170,335
29. Jan 19 Sell Citadel Group Limited Company 28. Jan 19 28. Jan 19 -27,741 €1.32 €-36,506
29. Jan 19 Buy Citadel Group Limited Company 28. Jan 19 28. Jan 19 12,923 €1.32 €17,011
28. Jan 19 Sell Citadel Group Limited Company 25. Jan 19 25. Jan 19 -27,407 €1.30 €-35,524
28. Jan 19 Buy Citadel Group Limited Company 25. Jan 19 25. Jan 19 24,762 €1.30 €32,034
25. Jan 19 Sell Citadel Group Limited Company 24. Jan 19 24. Jan 19 -62,513 €1.29 €-80,485
25. Jan 19 Buy Citadel Group Limited Company 24. Jan 19 24. Jan 19 70,479 €1.29 €90,701
30. Jan 19 Buy State Street Global Advisors, Inc. Company 29. Jan 19 29. Jan 19 471,574 €1.34 €631,366
30. Jan 19 Buy UBS Asset Management Company 29. Jan 19 29. Jan 19 10,349 €1.33 €13,743
30. Jan 19 Buy Brewin Dolphin Limited Company 29. Jan 19 29. Jan 19 28,431 €1.33 €37,954
30. Jan 19 Buy Charles Stanley & Co. Ltd, Asset Management Arm Company 29. Jan 19 29. Jan 19 14,670 €1.33 €19,571
29. Jan 19 Buy BlackRock, Inc. Company 28. Jan 19 28. Jan 19 31,572 €1.32 €41,635
29. Jan 19 Buy State Street Global Advisors, Inc. Company 28. Jan 19 28. Jan 19 1,473,111 €1.31 €1,923,228
29. Jan 19 Sell Brooks MacDonald Asset Management Limited Company 28. Jan 19 28. Jan 19 -3,464 €1.31 €-4,544
29. Jan 19 Buy Brooks MacDonald Asset Management Limited Company 28. Jan 19 28. Jan 19 55,000 €1.31 €72,144
29. Jan 19 Buy UBS Asset Management Company 28. Jan 19 28. Jan 19 10,162 €1.30 €13,213
28. Jan 19 Buy State Street Global Advisors, Inc. Company 25. Jan 19 25. Jan 19 1,130,821 €1.30 €1,465,254
24. Jan 19 Buy State Street Global Advisors, Inc. Company 23. Jan 19 23. Jan 19 2,358 €1.32 €3,116
29. Jan 19 Sell Charles Stanley & Co. Ltd, Asset Management Arm Company 28. Jan 19 28. Jan 19 -5,294 €1.32 €-6,978
29. Jan 19 Buy Charles Stanley & Co. Ltd, Asset Management Arm Company 28. Jan 19 28. Jan 19 78,650 €1.32 €103,079
28. Jan 19 Buy BlackRock, Inc. Company 25. Jan 19 25. Jan 19 15,243 €1.30 €19,855
28. Jan 19 Buy UBS Asset Management Company 25. Jan 19 25. Jan 19 9,987 €1.29 €12,923
25. Jan 19 Sell Brooks MacDonald Asset Management Limited Company 24. Jan 19 24. Jan 19 -5,000 €1.28 €-6,378
25. Jan 19 Buy BlackRock, Inc. Company 24. Jan 19 24. Jan 19 124,436 €1.29 €160,149
25. Jan 19 Buy Brewin Dolphin Limited Company 24. Jan 19 24. Jan 19 42,000 €1.29 €54,125
X
Management checks
We assess Primary Health Properties's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Primary Health Properties has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

PP51 News

Simply Wall St News

PP51 Company Info

Description

Primary Health Properties PLC (“PHP”) is a UK Real Estate Investment Trust (“REIT”) and the leading investor in modern primary healthcare premises. The objective of the Group is to create progressive returns to shareholders through a combination of earnings growth and capital appreciation. PHP achieves this by investing in healthcare real estate in the UK and Ireland let on long term leases backed by a secure underlying covenant funded mostly by government bodies.

Details
Name: Primary Health Properties Plc
PP51
Exchange: DB
Founded: 1995
£1,715,568,386
1,134,666,784
Website: http://www.phpgroup.co.uk
Address: Primary Health Properties Plc
Greener House,
5th Floor,
London,
East Lothian, SW1Y 4RF,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
LSE PHP Ordinary Shares London Stock Exchange GB GBP 19. Mar 1996
DB PP51 Ordinary Shares Deutsche Boerse AG DE EUR 19. Mar 1996
BATS-CHIXE PHPL Ordinary Shares BATS 'Chi-X Europe' GB GBP 19. Mar 1996
Number of employees
Current staff
Staff numbers
0
Primary Health Properties employees.
Industry
Health Care REITs
Real Estate
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/20 20:49
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/11
Last earnings filing: 2019/02/07
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.